Significant Wednesday Options Trading: NLOP, MSM, AHCO
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 03 2025
0mins
Should l Buy AHCO?
Source: NASDAQ.COM
MSC Industrial Direct Options Activity: MSC Industrial Direct Co Inc (MSM) has seen a significant options volume of 15,048 contracts today, equating to 1.5 million underlying shares, which is 235.9% of its average daily trading volume.
High Volume Put Option for MSM: The $80 strike put option expiring on January 16, 2026, has particularly high activity, with 5,042 contracts traded, representing about 504,200 underlying shares.
AdaptHealth Corp Options Activity: AdaptHealth Corp (AHCO) has recorded an options volume of 12,117 contracts today, amounting to 1.2 million underlying shares, or 104.9% of its average daily trading volume.
High Volume Call Option for AHCO: The $10 strike call option expiring on January 16, 2026, is notably active, with 6,065 contracts traded, representing approximately 606,500 underlying shares.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AHCO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AHCO
Wall Street analysts forecast AHCO stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 11.730
Low
13.00
Averages
13.00
High
13.00
Current: 11.730
Low
13.00
Averages
13.00
High
13.00
About AHCO
AdaptHealth Corp. is a provider of patient-centered, healthcare-at-home solutions including home medical equipment (HME), medical supplies, and related services. The Company provides a full suite of medical products and solutions designed to help patients manage chronic conditions in the home. Its product and service offerings include sleep therapy equipment, supplies, and related services (including CPAP and bi PAP services) to individuals suffering from obstructive sleep apnea; medical devices and supplies to patients for the treatment of diabetes, including continuous glucose monitors and insulin pumps; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home, and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy and nutritional supply needs. It operates in 50 states through its network of over 670 locations in 47 states.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
AdaptHealth Q1 2026 Earnings Call Insights
- Revenue Growth: In Q1 2026, AdaptHealth reported net revenue of $819.8 million, a 5.4% increase year-over-year, exceeding analysts' expectations of $796.6 million, indicating strong performance under the new capitated agreement, although adjusted EBITDA was $121.2 million, about $7 million lower than guidance due to transition labor costs.
- Strategic Expansion: The company established 35 new locations and became the exclusive HME provider for over 10 million new members, which not only enhances market share but also lays the groundwork for future revenue growth, particularly in the rapidly expanding Asia-Pacific region.
- Financial Outlook: AdaptHealth raised its full-year 2026 net revenue guidance to $3.45 billion to $3.52 billion, reflecting confidence in future growth, while maintaining adjusted EBITDA guidance between $680 million and $730 million, indicating stable profitability.
- Capital Structure Optimization: The company completed a $1.1 billion refinancing and plans to redeem its 2028 notes after August 2026, which is expected to improve its capital structure and reduce financial costs, thereby providing greater flexibility for future investments.
See More
AdaptHealth Q1 Earnings Beat Expectations with Revenue Growth
- Earnings Performance: AdaptHealth reported a Q1 GAAP EPS of -$0.12, missing expectations by $0.11, yet achieved revenue of $819.8 million, a 5.4% year-over-year increase that exceeded market expectations by $23.17 million, demonstrating resilience in revenue growth.
- Strong Organic Growth: The company reported an organic revenue growth rate of 9.1%, with growth across all reportable segments, indicating AdaptHealth's competitive position and sustained customer demand in the market.
- Guidance Increase for FY 2026: AdaptHealth raised its net revenue guidance for fiscal year 2026 by $10 million, now expecting net revenue between $3.45 billion and $3.52 billion, reflecting the company's confidence in future growth prospects.
- Cash Flow and EBITDA Guidance: The company maintained its adjusted EBITDA guidance between $680 million and $730 million, while projecting free cash flow between $175 million and $225 million, highlighting robust financial management and ongoing profitability.
See More
AdaptHealth Set to Announce Earnings, Market Expects Growth
- Earnings Announcement: AdaptHealth is set to release its earnings report this Tuesday, with the market anticipating a 2.5% year-on-year revenue growth, contrasting sharply with the 1.8% decline recorded in the same quarter last year, indicating the company's potential for recovery amidst challenges.
- Revenue Performance: Last quarter, AdaptHealth reported revenues of $846.3 million, down 1.2% year-on-year, which, while beating analysts' revenue expectations, saw a significant miss in EPS estimates, reflecting challenges in profitability.
- Market Sentiment: Investor sentiment in the senior health, home health, and hospice sectors has been positive, with average share prices rising 6% over the past month, while AdaptHealth's shares increased by 9.1%, indicating optimism about its future performance.
- Analyst Expectations: Most analysts have reaffirmed their estimates for AdaptHealth over the past 30 days, with an average price target of $13.19, slightly above the current share price of $13.17, suggesting a cautiously optimistic outlook for its growth prospects.
See More
Reinhart Partners Increases Stake in AdaptHealth by Nearly 2 Million Shares
- Share Accumulation: Reinhart Partners increased its stake in AdaptHealth by 1,981,198 shares during Q1 2026, with an estimated transaction value of $20.2 million, indicating growing confidence in the company and potentially boosting its stock performance.
- Increased Holdings Significance: Following this purchase, AdaptHealth now represents approximately 3.5% of Reinhart Partners' 13F reportable assets, highlighting the company's rising importance in the fund's portfolio and possibly attracting more institutional investor interest.
- Financial Performance: AdaptHealth reported revenue of $846.3 million in its latest earnings report, exceeding analyst expectations despite a roughly 1% year-over-year decline, while projecting net revenue of $3.44 billion to $3.51 billion for 2026, indicating potential business recovery.
- Enhanced Financing Capability: On April 13, AdaptHealth announced the closure of a $1.1 billion senior secured credit facility, reducing near-term refinancing risk and reflecting upgraded credit ratings, which bolsters market confidence in its future growth prospects.
See More
AdaptHealth Closes $1.1B Senior Secured Credit Facility
- Credit Facility Size: AdaptHealth announced the closure of a $1.1 billion senior secured credit facility, which includes a $325 million Term Loan A and a $450 million revolving credit, significantly enhancing the company's liquidity to support ongoing operations.
- Loan Utilization: The newly acquired $325 million term loan will be used to fully repay the existing term loan without penalty, optimizing the company's debt structure and reducing financing costs.
- Interest Rate Advantage: The new credit facility features a minimum interest rate reduced to 1.125% over SOFR, linked to the company's leverage ratio, which is expected to further lower financing costs during deleveraging, enhancing financial flexibility.
- Maturity Extension: The facility matures in April 2031, extending debt maturities by about two years, and is expected to lower the company's weighted average cost of debt by at least 25 basis points following the redemption of its 2028 senior notes, thereby strengthening the company's financial stability.
See More
Adobe CEO Resignation Triggers Stock Decline
- Adobe CEO Transition: Adobe's CEO Shantanu Narayen announced his resignation after a successor is named, causing shares to tumble over 5%, despite the company beating first-quarter earnings expectations, indicating market concerns over leadership changes.
- Fertilizer Stocks Retreat: Fertilizer companies' shares fell back due to ongoing disruptions in the Strait of Hormuz, with Intrepid Potash down about 8% and both Mosaic and CF Industries dropping around 4%, reflecting market sensitivity to raw material price fluctuations.
- Ulta Beauty Earnings Miss: Ulta Beauty reported fourth-quarter earnings of $8.01 per share, falling short of the $8.03 expected by analysts, leading to a 12% drop in stock price, despite revenue of $3.9 billion exceeding expectations, highlighting pressures on profitability.
- Once Upon A Farm Performance Decline: Once Upon A Farm reported its first earnings since going public, guiding for 2026 adjusted EBITDA of $2 million to $4 million, significantly lower than $6.6 million in Q4 2025, resulting in an 8% stock drop and raising concerns about future growth prospects.
See More
AdaptHealth Q1 2026 Earnings Call Insights
- Revenue Growth: In Q1 2026, AdaptHealth reported net revenue of $819.8 million, a 5.4% increase year-over-year, exceeding analysts' expectations of $796.6 million, indicating strong performance under the new capitated agreement, although adjusted EBITDA was $121.2 million, about $7 million lower than guidance due to transition labor costs.
- Strategic Expansion: The company established 35 new locations and became the exclusive HME provider for over 10 million new members, which not only enhances market share but also lays the groundwork for future revenue growth, particularly in the rapidly expanding Asia-Pacific region.
- Financial Outlook: AdaptHealth raised its full-year 2026 net revenue guidance to $3.45 billion to $3.52 billion, reflecting confidence in future growth, while maintaining adjusted EBITDA guidance between $680 million and $730 million, indicating stable profitability.
- Capital Structure Optimization: The company completed a $1.1 billion refinancing and plans to redeem its 2028 notes after August 2026, which is expected to improve its capital structure and reduce financial costs, thereby providing greater flexibility for future investments.
See More
AdaptHealth Q1 Earnings Beat Expectations with Revenue Growth
- Earnings Performance: AdaptHealth reported a Q1 GAAP EPS of -$0.12, missing expectations by $0.11, yet achieved revenue of $819.8 million, a 5.4% year-over-year increase that exceeded market expectations by $23.17 million, demonstrating resilience in revenue growth.
- Strong Organic Growth: The company reported an organic revenue growth rate of 9.1%, with growth across all reportable segments, indicating AdaptHealth's competitive position and sustained customer demand in the market.
- Guidance Increase for FY 2026: AdaptHealth raised its net revenue guidance for fiscal year 2026 by $10 million, now expecting net revenue between $3.45 billion and $3.52 billion, reflecting the company's confidence in future growth prospects.
- Cash Flow and EBITDA Guidance: The company maintained its adjusted EBITDA guidance between $680 million and $730 million, while projecting free cash flow between $175 million and $225 million, highlighting robust financial management and ongoing profitability.
See More
AdaptHealth Set to Announce Earnings, Market Expects Growth
- Earnings Announcement: AdaptHealth is set to release its earnings report this Tuesday, with the market anticipating a 2.5% year-on-year revenue growth, contrasting sharply with the 1.8% decline recorded in the same quarter last year, indicating the company's potential for recovery amidst challenges.
- Revenue Performance: Last quarter, AdaptHealth reported revenues of $846.3 million, down 1.2% year-on-year, which, while beating analysts' revenue expectations, saw a significant miss in EPS estimates, reflecting challenges in profitability.
- Market Sentiment: Investor sentiment in the senior health, home health, and hospice sectors has been positive, with average share prices rising 6% over the past month, while AdaptHealth's shares increased by 9.1%, indicating optimism about its future performance.
- Analyst Expectations: Most analysts have reaffirmed their estimates for AdaptHealth over the past 30 days, with an average price target of $13.19, slightly above the current share price of $13.17, suggesting a cautiously optimistic outlook for its growth prospects.
See More
Reinhart Partners Increases Stake in AdaptHealth by Nearly 2 Million Shares
- Share Accumulation: Reinhart Partners increased its stake in AdaptHealth by 1,981,198 shares during Q1 2026, with an estimated transaction value of $20.2 million, indicating growing confidence in the company and potentially boosting its stock performance.
- Increased Holdings Significance: Following this purchase, AdaptHealth now represents approximately 3.5% of Reinhart Partners' 13F reportable assets, highlighting the company's rising importance in the fund's portfolio and possibly attracting more institutional investor interest.
- Financial Performance: AdaptHealth reported revenue of $846.3 million in its latest earnings report, exceeding analyst expectations despite a roughly 1% year-over-year decline, while projecting net revenue of $3.44 billion to $3.51 billion for 2026, indicating potential business recovery.
- Enhanced Financing Capability: On April 13, AdaptHealth announced the closure of a $1.1 billion senior secured credit facility, reducing near-term refinancing risk and reflecting upgraded credit ratings, which bolsters market confidence in its future growth prospects.
See More
AdaptHealth Closes $1.1B Senior Secured Credit Facility
- Credit Facility Size: AdaptHealth announced the closure of a $1.1 billion senior secured credit facility, which includes a $325 million Term Loan A and a $450 million revolving credit, significantly enhancing the company's liquidity to support ongoing operations.
- Loan Utilization: The newly acquired $325 million term loan will be used to fully repay the existing term loan without penalty, optimizing the company's debt structure and reducing financing costs.
- Interest Rate Advantage: The new credit facility features a minimum interest rate reduced to 1.125% over SOFR, linked to the company's leverage ratio, which is expected to further lower financing costs during deleveraging, enhancing financial flexibility.
- Maturity Extension: The facility matures in April 2031, extending debt maturities by about two years, and is expected to lower the company's weighted average cost of debt by at least 25 basis points following the redemption of its 2028 senior notes, thereby strengthening the company's financial stability.
See More
Adobe CEO Resignation Triggers Stock Decline
- Adobe CEO Transition: Adobe's CEO Shantanu Narayen announced his resignation after a successor is named, causing shares to tumble over 5%, despite the company beating first-quarter earnings expectations, indicating market concerns over leadership changes.
- Fertilizer Stocks Retreat: Fertilizer companies' shares fell back due to ongoing disruptions in the Strait of Hormuz, with Intrepid Potash down about 8% and both Mosaic and CF Industries dropping around 4%, reflecting market sensitivity to raw material price fluctuations.
- Ulta Beauty Earnings Miss: Ulta Beauty reported fourth-quarter earnings of $8.01 per share, falling short of the $8.03 expected by analysts, leading to a 12% drop in stock price, despite revenue of $3.9 billion exceeding expectations, highlighting pressures on profitability.
- Once Upon A Farm Performance Decline: Once Upon A Farm reported its first earnings since going public, guiding for 2026 adjusted EBITDA of $2 million to $4 million, significantly lower than $6.6 million in Q4 2025, resulting in an 8% stock drop and raising concerns about future growth prospects.
See More
